These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24951139)

  • 1. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
    Yotsu RR; Richardson M; Ishii N
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin.
    Chauty A; Ardant MF; Marsollier L; Pluschke G; Landier J; Adeye A; Goundoté A; Cottin J; Ladikpo T; Ruf T; Ji B
    Clin Infect Dis; 2011 Jan; 52(1):94-6. PubMed ID: 21148526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
    Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined local and vaginal therapy in Buruli ulcer].
    Milánkovits M
    Orv Hetil; 2010 Aug; 151(35):1434-5. PubMed ID: 20824910
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.
    O'Brien DP; Jenkin G; Buntine J; Steffen CM; McDonald A; Horne S; Friedman ND; Athan E; Hughes A; Callan PP; Johnson PD
    Med J Aust; 2014 Mar; 200(5):267-70. PubMed ID: 24641151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort.
    Friedman ND; Athan E; Hughes AJ; Khajehnoori M; McDonald A; Callan P; Rahdon R; O'Brien DP
    PLoS Negl Trop Dis; 2013; 7(7):e2315. PubMed ID: 23875050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.
    Sugawara M; Ishii N; Nakanaga K; Suzuki K; Umebayashi Y; Makigami K; Aihara M
    J Dermatol; 2015 Jun; 42(6):588-95. PubMed ID: 25809502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
    Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
    Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection).
    Walsh DS; Portaels F; Meyers WM
    Curr Opin Infect Dis; 2010 Oct; 23(5):445-55. PubMed ID: 20581668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic management of
    Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bifocal Buruli ulcer: multiple cephalic lesions after initiation of medical treatment].
    Vagamon B; Ahogo KC; Aka BR; Diabaté A; Kouassi YI; Kourouma SH; Traoré C; Gue I; Yoboue P; Kanga JM; Taieb A
    Ann Dermatol Venereol; 2013 Feb; 140(2):125-8. PubMed ID: 23395495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
    Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
    BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.